HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCPC: 'Double Fees' For Cosmetic-Drug Products Are Regulatory Reform Concern

This article was originally published in The Rose Sheet

Executive Summary

Cosmetic products containing OTC drug ingredients – such as acne-fighting agents and UV filters in skin-care and makeup items, fluoride in toothpaste and dandruff medication in shampoo – could be subject to multiple fees if FDA's concept for generating OTC monograph program funding were to become a reality along with the Personal Care Products Safety Act.

You may also be interested in...



All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests

In an update on discussions with industry about potential user fees to support FDA's OTC monograph program, CDER officials say "industry and public would suffer" absent new fees.

Bausch + Lomb Rings Bell On 'Largest' Launch Year

Canadian firm’s eye health supplements Occuvite and PreserVision remain top sellers, with ReNu and Biotrue contact lens solutions and Lumify eye drops and skin care line rounding out its top 10 revenue generators.

Conservative-Backed Group Mitigates Penalties In False COVID-19 Claims Settlement With FTC

Precision Patient Outcomes' compliance costs from settlement with FTC “are not onerous,” says New Civil Liberties Alliance attorney John Vecchione. Settlement requires firm to notify customers and resellers about lawsuit and preserve all scientific evidence for health claims made for its products.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019953

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel